Open AccessP525: PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1‐MUTATED AML
Author(s) -
Byrd J. C.,
Cortes J. E.,
Minden M. D.,
Oellerich T.,
Stein E. M.,
Elder J.,
Kumar P.,
Bray G.,
DiMartino J.,
Stock W.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844988.96667.47
Subject(s) - cytarabine , idarubicin , medicine , myeloid leukemia , oncology , induction chemotherapy , daunorubicin , npm1 , myeloid , gastroenterology , chemotherapy , immunology , biology , biochemistry , karyotype , chromosome , gene